Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer: A phase IB study

A. Tubaro, F. Velotti, A. Stoppacciaro, A. Santoni, C. Vicentini, P. C. Bossola, P. Galassi, A. Pettinato, S. Morrone, T. Napolitano, L. Frati, L. Ruco, C. R. Franks, P. A. Palmer, C. N. Pourreau, L. Miano

Research output: Contribution to journal › Article

Abstract

Toxicity and clinical effects of intra-arterial (IA) continuous infusion of recombinant interleukin-2 (rIL-2) were evaluated in twelve patients with low-stage transitional cell carcinoma (TCC) of the bladder (T1NOMO; G1 to G2). rIL-2 dosages were escalated from 18 x 103 to 18 x 106 IU/m2/d in four groups of three patients. After two 5-day courses, separated by a 48- hour interval, evaluation of clinical response and transurethral resection (TUR) were carried out. World Health Organization (WHO) Grade 3 toxicity occurred in 2 of 12 patients (hypotension/mental confusion and fever, respectively); all side effects rapidly disappeared after infusion was abandoned. No laboratory toxicity developed in any patient. Two pathologically proven complete responses (CR) were achieved using 18 x 104 IU/m2/d, and three partial responses (PR) were achieved using 18 x 105 IU/m2/d in two patients and 18 x 106 IU/m2/d in one patient, giving an overall response rate of 42%. All objective responses are still ongoing after a mean follow-up time of 23 months (range, 12 to 32 months). Local relapses occurred 3 months after TUR only in two nonresponders.

Original languageEnglish
Pages (from-to)56-61
Number of pages6
JournalCancer
Volume68
Issue number1
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Access to Document

Fingerprint Dive into the research topics of 'Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer: A phase IB study'. Together they form a unique fingerprint.

    • Cite this

    Tubaro, A., Velotti, F., Stoppacciaro, A., Santoni, A., Vicentini, C., Bossola, P. C., Galassi, P., Pettinato, A., Morrone, S., Napolitano, T., Frati, L., Ruco, L., Franks, C. R., Palmer, P. A., Pourreau, C. N., & Miano, L. (1991). Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer: A phase IB study. Cancer, 68(1), 56-61.